{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"groups":[{"description":"Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG000","title":"EGFR: Erlotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG001","title":"EGFR: No Erlotinib"},{"description":"Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG002","title":"ALK: Crizotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG003","title":"ALK: No Crizotinib"}],"populationDescription":"The data required for this analysis was not obtained and will not be obtained.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Correlation Between Clinical Outcomes and Tumor Molecular Aberrations","type":"SECONDARY"}